Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2017 Jun 9;7(6):e014843.
doi: 10.1136/bmjopen-2016-014843.

Diagnostic value of the antiglycoprotein-2 antibody for Crohn's disease: a PRISMA-compliant systematic review and meta-analysis

Chuiwen Deng  1 , Wenli Li  2 , Jing Li  3 , Shulan Zhang  1 , Yongzhe Li  1
Affiliations
Meta-Analysis

Diagnostic value of the antiglycoprotein-2 antibody for Crohn's disease: a PRISMA-compliant systematic review and meta-analysis

Chuiwen Deng et al. BMJ Open. .

Abstract

Objectives: To perform a meta-analysis to evaluate the diagnostic performance of the antiglycoprotein-2 (GP2) antibody for Crohn's disease (CD).

Methods: Three databases (EMBASE, ISI Web of Knowledge and PubMed) were systematically searched. There were 17 eligible studies included in the meta-analysis. A total of 2439 patients with CD and 3184 controls were involved in these studies. STATA V.11.2 and Meta-DiSc V.1.4 were used to perform the meta-analysis.

Results: The area under the summary receiver operating characteristic curve was 0.68-0.72. The pooled diagnostic sensitivity of the anti-GP2 antibody ranged from 14% to 24%, and the specificity was 96%-98%.

Conclusions: The anti-GP2 antibody is a specific biomarker for CD, and further exploration of its prevalence among different clinical phenotypes of CD will provide a better understanding of its diagnostic performance.

Keywords: Anti-glycoprotein 2 antibody; Crohn's disease; Diagnostic performance; Meta-analysis.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Flow chart of studies included in the meta-analysis.
Figure 2
Figure 2
The forest plots and the summary receiver operating characteristic curves of antiglycoprotein 2 antibody (IgG) for CD. (A) Sensitivity forest plot; (B) specificity forest plot; (C) summary receiver operating characteristic (SROC).
Figure 3
Figure 3
The forest plots and the summary receiver operating characteristic curves of antiglycoprotein 2 antibody (IgA) for CD. (A) Sensitivity forest plot; (B) specificity forest plot; (C) summary receiver operating characteristic (SROC). CD, Crohn’s disease.
Figure 4
Figure 4
The forest plots and the summary receiver operating characteristic curves of antiglycoprotein 2 antibody (either IgG or IgA) for CD. (A) Sensitivity forest plot; (B) Specificity forest plot; (C) Summary receiver iperating characteristic (SROC). CD, Crohn’s disease.
Figure 5
Figure 5
Funnel plot of the publication bias for the antiglycoprotein 2 antibody (IgG and IgA either). ESS is the abbreviation of effective sample size.
See this image and copyright information in PMC

References

    1. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989;170:2–6. 10.3109/00365528909091339 - DOI - PubMed
    1. Laass MW, Roggenbuck D, Conrad K. Diagnosis and classification of Crohn's disease. Autoimmun Rev 2014;13:467–71. 10.1016/j.autrev.2014.01.029 - DOI - PubMed
    1. Bossuyt X. Serologic markers in inflammatory bowel disease. Clin Chem 2006;52:171–81. 10.1373/clinchem.2005.058560 - DOI - PubMed
    1. Roggenbuck D, Reinhold D, Wex T, et al. Autoantibodies to GP2, the major zymogen granule membrane glycoprotein, are new markers in Crohn's disease. Clin Chim Acta 2011;412:718–24. 10.1016/j.cca.2010.12.029 - DOI - PubMed
    1. Stöcker W, Otte M, Ulrich S, et al. Autoimmunity to pancreatic juice in Crohn's disease. Results of an autoantibody screening in patients with chronic inflammatory bowel disease. Scand J Gastroenterol Suppl 1987;139:41–52. - PubMed

LinkOut - more resources